CEFTRIAXONE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEFTRIAXONE IN PLASTIC CONTAINER (CEFTRIAXONE IN PLASTIC CONTAINER).
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged in the urine (33-67%) and bile (up to 40%). It undergoes minimal hepatic metabolism. |
| Excretion | Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites). |
| Half-life | 5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment. |
| Protein binding | 85-95% bound to albumin. |
| Volume of Distribution | 0.2-0.4 L/kg; indicates extensive distribution into interstitial fluid and tissues. |
| Bioavailability | IM: 100%. |
| Onset of Action | IV: Immediate; IM: 1-2 hours. |
| Duration of Action | 24 hours; allows once-daily dosing due to prolonged half-life. |
| Molecular Weight | 554.58 |
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 10-50 mL/min: no adjustment needed; for GFR <10 mL/min: maximum dose 2 g every 24 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B and C: no dosage adjustment required as hepatic metabolism is minimal. |
| Pediatric use | 50-75 mg/kg/day intravenously or intramuscularly divided every 12-24 hours, maximum 2 g/day. |
| Geriatric use | No specific adjustment except based on renal function; monitor renal function and adjust per creatinine clearance. |
| 1st trimester | Generally considered safe; no evidence of teratogenicity in animal studies. Limited human data, but no increased risk of major malformations reported. |
| 2nd trimester | Safe for use; crosses placenta with therapeutic fetal levels achieved. No known fetal harm. |
| 3rd trimester | Safe; may be used for maternal infections including intra-amniotic infection. No risk of kernicterus despite theoretical bilirubin displacement. |
Clinical note
Comprehensive clinical and safety monograph for CEFTRIAXONE IN PLASTIC CONTAINER (CEFTRIAXONE IN PLASTIC CONTAINER).
| Placental transfer | Crosses placenta readily; achieves fetal serum concentrations approximately 1-10% of maternal levels. Higher transfer in late gestation. |
| Breastfeeding | Excreted into breast milk in low concentrations (approximately 4% of maternal weight-adjusted dose). Not expected to cause adverse effects in breastfed infants. Considered compatible with breastfeeding. |
■ FDA Black Box Warning
None. Ceftriaxone does not have an FDA black box warning.
| Serious Effects |
Known hypersensitivity to cephalosporins or any componentPrevious immediate hypersensitivity reaction to any beta-lactam (e.g., anaphylaxis to penicillins) – caution; not absolute but generally avoidHyperbilirubinemic neonates (especially preterm) due to risk of bilirubin encephalopathy
| Precautions | Hypersensitivity reactions, including anaphylaxis, have been reported., Clostridium difficile-associated diarrhea (CDAD) may occur., Concomitant use with calcium-containing IV solutions can cause fatal precipitation in neonates., Hemolytic anemia, immune-mediated, has been reported., Seizures may occur in patients with renal impairment receiving high doses., Biliary pseudolithiasis has been observed., Prolonged prothrombin time possible; monitor in patients with vitamin K deficiency. |
| Food/Dietary | No specific food interactions, but avoid alcohol due to disulfiram-like reaction (nausea, vomiting, headache). |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Ceftriaxone is a pregnancy category B drug. Animal studies have not demonstrated fetal risk, and there are no adequate well-controlled studies in pregnant women. However, it should be used during pregnancy only if clearly needed. No known teratogenic effects in first trimester; potential for bilirubin displacement in third trimester, but clinical significance is minimal. |
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy care. Observe for signs of maternal allergic reactions, diarrhea (Clostridium difficile colitis), and neonatal effects if administered near delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data insufficient to determine impact. |
| Clinical Pearls | Administer IV over 30 minutes; do not mix with calcium-containing solutions (risk of precipitation). Use with caution in neonates with hyperbilirubinemia (displaces bilirubin). Monitor renal function during therapy. Can cause biliary sludge/pseudolithiasis. Antagonized by chloramphenicol. |
| Patient Advice | This medication is given intravenously; tell your nurse if you experience pain or redness at the injection site. · Report any signs of allergic reaction: rash, itching, swelling, difficulty breathing. · Diarrhea is common; contact your doctor if severe or bloody diarrhea occurs (may indicate C. diff). · Do not drink alcohol during treatment and for 48 hours after stopping (risk of disulfiram-like reaction). · Inform your doctor if you have a history of gallbladder problems (ceftriaxone can cause gallbladder sludge). |